Organogels, hydrogels and bigels as transdermal delivery systems for diltiazem HCL

Asian Journal of Pharmaceutical Sciences

Volumn 8, Issue 1, 2013, Pages 46-54

  Ibrahim, Mahmoud Mokhtar ^a,b   Hafez, Salma A ^a   Mahdy, Mahmoud M ^a  

^a Zagazig University   (Egypt)

^b NAJRAN UNIVERSITY   (Saudi Arabia)

Author keywords

Bigels; Hydrogels; Lecithin; Organogels; Span

Indexed keywords

CELLOPHANE; DILTIAZEM; HEXADECANOL; HYDROXYPROPYLMETHYLCELLULOSE; PHOSPHATIDYLCHOLINE; POLOXAMER; POLYSORBATE 20; POLYSORBATE 80; SORBITAN OLEATE; SOYBEAN OIL; SURFACTANT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG PENETRATION; DRUG RELEASE; EMULSION; GEL; HYDROGEL; HYPERTENSION; IN VIVO STUDY; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; OLEOHYDROGEL; ORGANOGEL; PH; RAT; THERMAL ANALYSIS; VISCOSITY;

EID: 84881339750     PISSN: 18180876     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Barrat GM. Therapeutic applications of colloidal drug carriers. Pharm Sci Technol Today. 2000, 3: 163-171.
2. O'Connor SE, Grosset A, Janiak P. The pharmacological basis and pathophysiological significance of the heart rate lowering property of diltiazem. Fundam Clin Pharmacol. 1999, 13 (2): 145-153.
3. Margret C., Chandramohan, Debjit et al. Design and characterisation of sustain release gastro retentive floating tablets of diltiazem hydrochloride. Der Pharmacia Lettre. 2009, 1 (2): 25-38.
4. Gannu R, Vishnu YV, Kishan V, et al. Development of nitrendipin transdermal patches. Curr Drug Deliv. 2007, 4: 69-76.
5. Rajesh K, Pitchaimani R. Formulation of transdermal drug delivery system. Curr Drug Discov Technolo. 2006, 3: 279-285.
6. Eaglstein WH. Moist wound healing with occlusive dressings: a clinical focus. Dermatol Surg. 2001, 27: 175-181.
7. Murdan S. Organogels in drug delivery. Expert Opin Drug Del. 2005, 2: 489-505.
8. Terech P, Weiss RG. Low molecular mass gelators of organic liquids and the properties of their gels. Chem Rev. 1997, 97: 3133-3160.
9. Shchipunov YA. Lecithin organogel: a micellar system with unique properties. Colloids Surf A Physicochem Eng Asp. 2001, 183-185: 541-554.
10. Murdan S. A review of pluronic lecithin organogel as a topical and transdermal drug delivery system. Hosp Pharmacist. 2005, 12: 267-270.
11. Almeida IF, Fernandes AR, Fernandes L, et al. Moisturizing effect of oleogel/hydrogel mixtures. Pharm Dev Technol. 2008, 13: 487-494.
12. Shaikh IM, Jadhav SL, Jadhav KR, et al. Aceclofenac Organogels: in vitro and in vivo characterization. Curr Drug Deliv. 2009, 6: 1-7.
13. Lognathan V, Manimaran S, Jaswanth A, et al. The effect of polymers and permeation enhancers on release of flubiprofen from gel formulations. Ind J Pharm Sci. 2001, 63 (3): 200-204.
14. Mahmoud MI, Omaima AS, Mohamed AH, et al. In vitro evaluation of proniosomes as a drug carrier for flurbiprofen. AAPS Pharm Sci Tech. 2008, 9(3): 782-790.
15. Ghazy FS, Ghareeb SA, Mahdy MA, et al. Comparative in vitro and in vivo studies of transdermal absorption of certain vasodilators. Alex J Pharm Sci. 2004, 18(2): 151-158.
16. Mura P, Faucci MT, Bramanti G, et al. Evaluation of transcutol as a clonazepam transdermal permeation enhancer from hydrophilic gel formulations. Eur J Pharm Sci. 2000, 9: 365-372.
17. Cangiano JL, Rodriguez SC, Martinez MM. J Pharmacol Exp Ther. 1979, 208 (2): 310-313.
18. Douglas JR, Johnson EM, Heist JF, et al. J Pharmacol Exp Therap. 1976, 196: 35-43.
19. Paget GE, Barnes JM. Interspecies dosage conversion schem in evaluation of results and quantitative application in different species. In: Evaluation of drug activities: pharmacometrics. Laurence DR and Bacharach AL (eds.), Academic press, London, New York, 1964, 1: 160-162.
20. Amidon GL, Lennernas H, Shah VP, et al. A therotical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res. 1995, 12: 413-420.
21. Burden DT, Balber LC, NatoffIL. A simple method for recording left ventricular pressure and heart rate in cats. J Pharmacol Ther. 1979, 5: 99-102.
22. Darne B, Girerd X, Safar M, et al. Pulsatile versus steady component of blood pressure: A cross-sectional analysis and a prospective analysis on cardiovascular mortality. Hypertension. 1989, 13(4): 392-400.
23. Trivedi DR, Ballabh A, Dastidar P, et al. Structure property correlation of a new family of Organogelators based on organic salts and their selective gelation of oil from oil/water mixtures. Chemistry. 2004, 10: 5311-5322.
24. Effendy I, Maibach HI. Surfactants and experimental irritant contact dermatitis. Contact Dermatitis. 1995, 33(4): 217-225.
25. Mazzo DJ, Obetz CL, Shuster J. Diltiazem hydrochloride. Analytical profiles of drug substances and excepients. in: Britain HG. (ed.), Academic Press, San Diego. 1994, 23: 54-98.
26. Sultana Y, Mall S, Maurya D, et al. Preparation and in vitro characterization of diltiazem hydrochloride loaded alginate microspheres. Pharm Dev Tech. 2009, 14(3): 321-331.
27. Worth AP, Cronin MTD. The use of pH measurements to predict the potential of chemicals to cause acute dermal and ocular toxicity. Toxicology. 2001, 169: 119-131.
28. Ruíz MMA, Gallardo JLV, Benavides MM, et al. Rheological behavior of gels and meloxicam release. Int J Pharm. 2007, 333: 17-23.
29. Vintiloiu A, Leroux JC. Organogels and their use in drug delivery-A review. J Control Rel. 2008, 125(3): 179-192.
30. Yang Y, Wang S, Xua H, et al. Properties of topically applied organogels: rheology and in vitro drug release. Asian J Pharm Sci. 2008, 3(4): 175-183.
31. Nokhodchi A, Khaseh P, Ghafourian T, et al. The role of various surfactants and fillersin controlling the release rate of theophylline from HPMC matrices. STP Pharma Sci. 1999, 9: 555-60
32. Pisal S, Shelke V, Mahadik K, et al Effect of organogel components on in vitro nasal delivery of propranolol hydrochloride. AAPS PharmSciTech. 2004, 5(4): 92-100.
33. Yaghmur A, Campo L, Aserin A, et al. Structural characterization of five component food grade oil in water nonionic microemulsions. Phys Chem Chem Phys. 2004, 6(7): 1524-1533.
34. Murdan S, Gregoriadis G, Florence AT. Non-ionic surfactant organogels incorporating niosomes. STP Pharma Sci. 1996, 6:44-48.
35. Cociello T, Matricardi P, Marianecci C, et al. Polysaccharide hydrogels for modified release formulations. J Control Rel. 2007, 119: 5-24.
36. Gupta S. Bicompatible microemulsion systems for drug encapsulation and delivery. Curr Sci. 2011, 101(2): 174-188.
37. Phaechamud T. Variables influencing drug release from layered matrix system comprising hydroxypropyl methylcellulose. AAPS PharmSciTech. 2008, 9(2): 668-674.
38. Lehmann KA, Zech D. Transdermal fentanyl clinical pharmacology. J Pain Symptom Manage. 1992, 7:S8-S16.
39. Ghosal K, Chakrabarty S, Nanda A. Hydroxypropyl methylcellulose in drug delivery. Der Pharmacia Sinica. 2011, 2 (2): 152-168.
40. Scartazzini R, Luisi PL. Organogels from Lecithins. J phys Chem. 1988, 92(3): 829-833.
41. Willimann H, Walde P, Lusi PL, et al. Lecithin organogels as matrix for transdermal transport of drugs. J Pharm Sci. 1992, 81: 871-874.